Cybin Inc. (CYBN.NE)
- Previous Close
0.4850 - Open
0.5000 - Bid 0.4600 x --
- Ask 0.4800 x --
- Day's Range
0.4650 - 0.5000 - 52 Week Range
0.3000 - 0.9800 - Volume
213,488 - Avg. Volume
330,201 - Market Cap (intraday)
368.468M - Beta (5Y Monthly) 0.96
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.
www.cybin.comRecent News: CYBN.NE
Performance Overview: CYBN.NE
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CYBN.NE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CYBN.NE
Valuation Measures
Market Cap
364.67M
Enterprise Value
326.04M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.01
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-4.87
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-44.21%
Return on Equity (ttm)
-79.36%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-70.45M
Diluted EPS (ttm)
-0.3000
Balance Sheet and Cash Flow
Total Cash (mrq)
39M
Total Debt/Equity (mrq)
0.30%
Levered Free Cash Flow (ttm)
-27.84M
Company Insights: CYBN.NE
CYBN.NE does not have Company Insights